nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.635	1	CiPCiCtD
Vemurafenib—ORM1—Erlotinib—pancreatic cancer	0.0238	0.0931	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—pancreatic cancer	0.0202	0.0788	CbGbCtD
Vemurafenib—ABCC1—Irinotecan—pancreatic cancer	0.0196	0.0767	CbGbCtD
Vemurafenib—ABCG2—Tamoxifen—pancreatic cancer	0.0171	0.0668	CbGbCtD
Vemurafenib—ABCG2—Erlotinib—pancreatic cancer	0.0145	0.0568	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—pancreatic cancer	0.0144	0.0562	CbGbCtD
Vemurafenib—ABCG2—Irinotecan—pancreatic cancer	0.0131	0.0513	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—pancreatic cancer	0.0126	0.0492	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—pancreatic cancer	0.0107	0.0419	CbGbCtD
Vemurafenib—ALB—Erlotinib—pancreatic cancer	0.01	0.0392	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—pancreatic cancer	0.00963	0.0376	CbGbCtD
Vemurafenib—ABCG2—Sunitinib—pancreatic cancer	0.00958	0.0374	CbGbCtD
Vemurafenib—ALB—Irinotecan—pancreatic cancer	0.00905	0.0354	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—pancreatic cancer	0.00887	0.0346	CbGbCtD
Vemurafenib—ALB—Fluorouracil—pancreatic cancer	0.00869	0.0339	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—pancreatic cancer	0.00718	0.028	CbGbCtD
Vemurafenib—CYP1A2—Tamoxifen—pancreatic cancer	0.00705	0.0276	CbGbCtD
Vemurafenib—CYP1A2—Erlotinib—pancreatic cancer	0.006	0.0234	CbGbCtD
Vemurafenib—CYP2D6—Tamoxifen—pancreatic cancer	0.00581	0.0227	CbGbCtD
Vemurafenib—CYP1A2—Fluorouracil—pancreatic cancer	0.0052	0.0203	CbGbCtD
Vemurafenib—CYP2D6—Erlotinib—pancreatic cancer	0.00494	0.0193	CbGbCtD
Vemurafenib—CYP3A4—Tamoxifen—pancreatic cancer	0.0037	0.0144	CbGbCtD
Vemurafenib—CYP3A4—Erlotinib—pancreatic cancer	0.00314	0.0123	CbGbCtD
Vemurafenib—CYP3A4—Irinotecan—pancreatic cancer	0.00284	0.0111	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—pancreatic cancer	0.00244	0.00952	CbGbCtD
Vemurafenib—CYP3A4—Docetaxel—pancreatic cancer	0.00208	0.00812	CbGbCtD
Vemurafenib—CYP3A4—Sunitinib—pancreatic cancer	0.00207	0.00809	CbGbCtD
Vemurafenib—RAF1—Topotecan—Irinotecan—pancreatic cancer	0.0018	1	CbGdCrCtD
Vemurafenib—CYP3A4—Doxorubicin—pancreatic cancer	0.00155	0.00606	CbGbCtD
Vemurafenib—ORM1—bile—pancreatic cancer	0.00111	0.438	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—pancreatic cancer	0.000454	1	CrCbGaD
Vemurafenib—ORM1—gall bladder—pancreatic cancer	0.000309	0.122	CbGeAlD
Vemurafenib—RAF1—islet of Langerhans—pancreatic cancer	0.000294	0.116	CbGeAlD
Vemurafenib—ALB—gall bladder—pancreatic cancer	0.000271	0.107	CbGeAlD
Vemurafenib—RAF1—pancreas—pancreatic cancer	0.000207	0.0812	CbGeAlD
Vemurafenib—RAF1—digestive system—pancreatic cancer	0.000176	0.0694	CbGeAlD
Vemurafenib—Infection—Sunitinib—pancreatic cancer	0.000116	0.00228	CcSEcCtD
Vemurafenib—Constipation—Erlotinib—pancreatic cancer	0.000115	0.00227	CcSEcCtD
Vemurafenib—Erythema—Gemcitabine—pancreatic cancer	0.000115	0.00226	CcSEcCtD
Vemurafenib—Alopecia—Fluorouracil—pancreatic cancer	0.000115	0.00225	CcSEcCtD
Vemurafenib—Nervous system disorder—Sunitinib—pancreatic cancer	0.000114	0.00225	CcSEcCtD
Vemurafenib—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000114	0.00224	CcSEcCtD
Vemurafenib—Back pain—Irinotecan—pancreatic cancer	0.000114	0.00224	CcSEcCtD
Vemurafenib—Neoplasm—Epirubicin—pancreatic cancer	0.000114	0.00223	CcSEcCtD
Vemurafenib—Skin disorder—Sunitinib—pancreatic cancer	0.000113	0.00223	CcSEcCtD
Vemurafenib—Erythema—Fluorouracil—pancreatic cancer	0.000113	0.00222	CcSEcCtD
Vemurafenib—Back pain—Gemcitabine—pancreatic cancer	0.000111	0.00218	CcSEcCtD
Vemurafenib—Body temperature increased—Erlotinib—pancreatic cancer	0.000107	0.0021	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000106	0.00209	CcSEcCtD
Vemurafenib—Weight decreased—Docetaxel—pancreatic cancer	0.000106	0.00208	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.000106	0.00208	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—pancreatic cancer	0.000105	0.00207	CcSEcCtD
Vemurafenib—Infestation—Docetaxel—pancreatic cancer	0.000104	0.00205	CcSEcCtD
Vemurafenib—Infestation NOS—Docetaxel—pancreatic cancer	0.000104	0.00205	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—pancreatic cancer	0.000104	0.00204	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.000103	0.00203	CcSEcCtD
Vemurafenib—Cough—Irinotecan—pancreatic cancer	0.000103	0.00202	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.000102	0.00201	CcSEcCtD
Vemurafenib—Decreased appetite—Sunitinib—pancreatic cancer	0.000101	0.00199	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000101	0.00198	CcSEcCtD
Vemurafenib—Fatigue—Sunitinib—pancreatic cancer	0.000101	0.00198	CcSEcCtD
Vemurafenib—Hypersensitivity—Tamoxifen—pancreatic cancer	0.0001	0.00197	CcSEcCtD
Vemurafenib—Cough—Gemcitabine—pancreatic cancer	0.0001	0.00197	CcSEcCtD
Vemurafenib—Constipation—Sunitinib—pancreatic cancer	9.98e-05	0.00196	CcSEcCtD
Vemurafenib—Asthenia—Tamoxifen—pancreatic cancer	9.78e-05	0.00192	CcSEcCtD
Vemurafenib—Arthralgia—Gemcitabine—pancreatic cancer	9.77e-05	0.00192	CcSEcCtD
Vemurafenib—Myalgia—Gemcitabine—pancreatic cancer	9.77e-05	0.00192	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	9.7e-05	0.00191	CcSEcCtD
Vemurafenib—Asthenia—Erlotinib—pancreatic cancer	9.67e-05	0.0019	CcSEcCtD
Vemurafenib—Pruritus—Tamoxifen—pancreatic cancer	9.64e-05	0.0019	CcSEcCtD
Vemurafenib—Anaphylactic shock—Irinotecan—pancreatic cancer	9.62e-05	0.00189	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—pancreatic cancer	9.61e-05	0.00189	CcSEcCtD
Vemurafenib—Myalgia—Fluorouracil—pancreatic cancer	9.61e-05	0.00189	CcSEcCtD
Vemurafenib—Infection—Irinotecan—pancreatic cancer	9.55e-05	0.00188	CcSEcCtD
Vemurafenib—Pruritus—Erlotinib—pancreatic cancer	9.54e-05	0.00188	CcSEcCtD
Vemurafenib—Nervous system disorder—Irinotecan—pancreatic cancer	9.43e-05	0.00185	CcSEcCtD
Vemurafenib—Anaphylactic shock—Gemcitabine—pancreatic cancer	9.37e-05	0.00184	CcSEcCtD
Vemurafenib—Diarrhoea—Tamoxifen—pancreatic cancer	9.33e-05	0.00183	CcSEcCtD
Vemurafenib—Infection—Gemcitabine—pancreatic cancer	9.31e-05	0.00183	CcSEcCtD
Vemurafenib—Body temperature increased—Sunitinib—pancreatic cancer	9.23e-05	0.00181	CcSEcCtD
Vemurafenib—Diarrhoea—Erlotinib—pancreatic cancer	9.23e-05	0.00181	CcSEcCtD
Vemurafenib—Oedema peripheral—Docetaxel—pancreatic cancer	9.22e-05	0.00181	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fluorouracil—pancreatic cancer	9.21e-05	0.00181	CcSEcCtD
Vemurafenib—Connective tissue disorder—Docetaxel—pancreatic cancer	9.19e-05	0.00181	CcSEcCtD
Vemurafenib—Nervous system disorder—Gemcitabine—pancreatic cancer	9.19e-05	0.00181	CcSEcCtD
Vemurafenib—Infection—Fluorouracil—pancreatic cancer	9.15e-05	0.0018	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—pancreatic cancer	9.12e-05	0.00179	CcSEcCtD
Vemurafenib—Skin disorder—Gemcitabine—pancreatic cancer	9.1e-05	0.00179	CcSEcCtD
Vemurafenib—Nervous system disorder—Fluorouracil—pancreatic cancer	9.03e-05	0.00177	CcSEcCtD
Vemurafenib—Dizziness—Tamoxifen—pancreatic cancer	9.01e-05	0.00177	CcSEcCtD
Vemurafenib—Hypotension—Irinotecan—pancreatic cancer	8.98e-05	0.00177	CcSEcCtD
Vemurafenib—Dizziness—Erlotinib—pancreatic cancer	8.92e-05	0.00175	CcSEcCtD
Vemurafenib—Erythema multiforme—Docetaxel—pancreatic cancer	8.85e-05	0.00174	CcSEcCtD
Vemurafenib—Hypotension—Gemcitabine—pancreatic cancer	8.75e-05	0.00172	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—pancreatic cancer	8.74e-05	0.00172	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—pancreatic cancer	8.68e-05	0.00171	CcSEcCtD
Vemurafenib—Vomiting—Tamoxifen—pancreatic cancer	8.67e-05	0.0017	CcSEcCtD
Vemurafenib—Hypotension—Fluorouracil—pancreatic cancer	8.61e-05	0.00169	CcSEcCtD
Vemurafenib—Hypersensitivity—Sunitinib—pancreatic cancer	8.6e-05	0.00169	CcSEcCtD
Vemurafenib—Rash—Tamoxifen—pancreatic cancer	8.59e-05	0.00169	CcSEcCtD
Vemurafenib—Dermatitis—Tamoxifen—pancreatic cancer	8.59e-05	0.00169	CcSEcCtD
Vemurafenib—Vomiting—Erlotinib—pancreatic cancer	8.57e-05	0.00169	CcSEcCtD
Vemurafenib—Headache—Tamoxifen—pancreatic cancer	8.54e-05	0.00168	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	8.53e-05	0.00168	CcSEcCtD
Vemurafenib—Rash—Erlotinib—pancreatic cancer	8.5e-05	0.00167	CcSEcCtD
Vemurafenib—Dermatitis—Erlotinib—pancreatic cancer	8.49e-05	0.00167	CcSEcCtD
Vemurafenib—Angiopathy—Docetaxel—pancreatic cancer	8.49e-05	0.00167	CcSEcCtD
Vemurafenib—Headache—Erlotinib—pancreatic cancer	8.45e-05	0.00166	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—pancreatic cancer	8.44e-05	0.00166	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—pancreatic cancer	8.43e-05	0.00166	CcSEcCtD
Vemurafenib—Chills—Docetaxel—pancreatic cancer	8.39e-05	0.00165	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	8.39e-05	0.00165	CcSEcCtD
Vemurafenib—Asthenia—Sunitinib—pancreatic cancer	8.38e-05	0.00165	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—pancreatic cancer	8.36e-05	0.00164	CcSEcCtD
Vemurafenib—Decreased appetite—Irinotecan—pancreatic cancer	8.36e-05	0.00164	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	8.3e-05	0.00163	CcSEcCtD
Vemurafenib—Fatigue—Irinotecan—pancreatic cancer	8.29e-05	0.00163	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—pancreatic cancer	8.27e-05	0.00162	CcSEcCtD
Vemurafenib—Pruritus—Sunitinib—pancreatic cancer	8.26e-05	0.00162	CcSEcCtD
Vemurafenib—Constipation—Irinotecan—pancreatic cancer	8.22e-05	0.00162	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	8.21e-05	0.00161	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—pancreatic cancer	8.14e-05	0.0016	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—pancreatic cancer	8.14e-05	0.0016	CcSEcCtD
Vemurafenib—Decreased appetite—Gemcitabine—pancreatic cancer	8.14e-05	0.0016	CcSEcCtD
Vemurafenib—Nausea—Tamoxifen—pancreatic cancer	8.1e-05	0.00159	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	8.09e-05	0.00159	CcSEcCtD
Vemurafenib—Fatigue—Gemcitabine—pancreatic cancer	8.08e-05	0.00159	CcSEcCtD
Vemurafenib—Constipation—Gemcitabine—pancreatic cancer	8.01e-05	0.00157	CcSEcCtD
Vemurafenib—Nausea—Erlotinib—pancreatic cancer	8.01e-05	0.00157	CcSEcCtD
Vemurafenib—Decreased appetite—Fluorouracil—pancreatic cancer	8.01e-05	0.00157	CcSEcCtD
Vemurafenib—Diarrhoea—Sunitinib—pancreatic cancer	7.99e-05	0.00157	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—pancreatic cancer	7.98e-05	0.00157	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	7.95e-05	0.00156	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—pancreatic cancer	7.88e-05	0.00155	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—pancreatic cancer	7.81e-05	0.00153	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—pancreatic cancer	7.74e-05	0.00152	CcSEcCtD
Vemurafenib—Dizziness—Sunitinib—pancreatic cancer	7.72e-05	0.00152	CcSEcCtD
Vemurafenib—Body temperature increased—Irinotecan—pancreatic cancer	7.6e-05	0.00149	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	7.6e-05	0.00149	CcSEcCtD
Vemurafenib—Vomiting—Sunitinib—pancreatic cancer	7.42e-05	0.00146	CcSEcCtD
Vemurafenib—Body temperature increased—Gemcitabine—pancreatic cancer	7.4e-05	0.00146	CcSEcCtD
Vemurafenib—Rash—Sunitinib—pancreatic cancer	7.36e-05	0.00145	CcSEcCtD
Vemurafenib—Dermatitis—Sunitinib—pancreatic cancer	7.35e-05	0.00145	CcSEcCtD
Vemurafenib—Headache—Sunitinib—pancreatic cancer	7.31e-05	0.00144	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—pancreatic cancer	7.28e-05	0.00143	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—pancreatic cancer	7.22e-05	0.00142	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—pancreatic cancer	7.2e-05	0.00141	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—pancreatic cancer	7.13e-05	0.0014	CcSEcCtD
Vemurafenib—Cough—Docetaxel—pancreatic cancer	7.11e-05	0.0014	CcSEcCtD
Vemurafenib—Hypersensitivity—Irinotecan—pancreatic cancer	7.08e-05	0.00139	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—pancreatic cancer	7.03e-05	0.00138	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—pancreatic cancer	7.03e-05	0.00138	CcSEcCtD
Vemurafenib—CYP1A2—digestive system—pancreatic cancer	7.02e-05	0.0276	CbGeAlD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	6.97e-05	0.00137	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—pancreatic cancer	6.93e-05	0.00136	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—pancreatic cancer	6.93e-05	0.00136	CcSEcCtD
Vemurafenib—Nausea—Sunitinib—pancreatic cancer	6.93e-05	0.00136	CcSEcCtD
Vemurafenib—Asthenia—Irinotecan—pancreatic cancer	6.9e-05	0.00136	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—pancreatic cancer	6.89e-05	0.00135	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	6.89e-05	0.00135	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—pancreatic cancer	6.79e-05	0.00133	CcSEcCtD
Vemurafenib—Asthenia—Gemcitabine—pancreatic cancer	6.72e-05	0.00132	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	6.66e-05	0.00131	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—pancreatic cancer	6.65e-05	0.00131	CcSEcCtD
Vemurafenib—Pruritus—Gemcitabine—pancreatic cancer	6.63e-05	0.0013	CcSEcCtD
Vemurafenib—Infection—Docetaxel—pancreatic cancer	6.6e-05	0.0013	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—pancreatic cancer	6.6e-05	0.0013	CcSEcCtD
Vemurafenib—Diarrhoea—Irinotecan—pancreatic cancer	6.58e-05	0.00129	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—pancreatic cancer	6.52e-05	0.00128	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—pancreatic cancer	6.52e-05	0.00128	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—pancreatic cancer	6.5e-05	0.00128	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—pancreatic cancer	6.5e-05	0.00128	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—pancreatic cancer	6.46e-05	0.00127	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	6.45e-05	0.00127	CcSEcCtD
Vemurafenib—Diarrhoea—Gemcitabine—pancreatic cancer	6.41e-05	0.00126	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.38e-05	0.00125	CcSEcCtD
Vemurafenib—Dizziness—Irinotecan—pancreatic cancer	6.36e-05	0.00125	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—pancreatic cancer	6.3e-05	0.00124	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—pancreatic cancer	6.22e-05	0.00122	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—pancreatic cancer	6.21e-05	0.00122	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—pancreatic cancer	6.2e-05	0.00122	CcSEcCtD
Vemurafenib—Vomiting—Irinotecan—pancreatic cancer	6.11e-05	0.0012	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—pancreatic cancer	6.09e-05	0.0012	CcSEcCtD
Vemurafenib—Rash—Irinotecan—pancreatic cancer	6.06e-05	0.00119	CcSEcCtD
Vemurafenib—Dermatitis—Irinotecan—pancreatic cancer	6.06e-05	0.00119	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.06e-05	0.00119	CcSEcCtD
Vemurafenib—Headache—Irinotecan—pancreatic cancer	6.02e-05	0.00118	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—pancreatic cancer	5.97e-05	0.00117	CcSEcCtD
Vemurafenib—Vomiting—Gemcitabine—pancreatic cancer	5.96e-05	0.00117	CcSEcCtD
Vemurafenib—Rash—Gemcitabine—pancreatic cancer	5.91e-05	0.00116	CcSEcCtD
Vemurafenib—Dermatitis—Gemcitabine—pancreatic cancer	5.9e-05	0.00116	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—pancreatic cancer	5.9e-05	0.00116	CcSEcCtD
Vemurafenib—Headache—Gemcitabine—pancreatic cancer	5.87e-05	0.00115	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—pancreatic cancer	5.86e-05	0.00115	CcSEcCtD
Vemurafenib—Vomiting—Fluorouracil—pancreatic cancer	5.86e-05	0.00115	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—pancreatic cancer	5.81e-05	0.00114	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—pancreatic cancer	5.8e-05	0.00114	CcSEcCtD
Vemurafenib—Decreased appetite—Docetaxel—pancreatic cancer	5.78e-05	0.00114	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—pancreatic cancer	5.77e-05	0.00113	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—pancreatic cancer	5.75e-05	0.00113	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.74e-05	0.00113	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.74e-05	0.00113	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—pancreatic cancer	5.73e-05	0.00113	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—pancreatic cancer	5.73e-05	0.00113	CcSEcCtD
Vemurafenib—Nausea—Irinotecan—pancreatic cancer	5.71e-05	0.00112	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—pancreatic cancer	5.69e-05	0.00112	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—pancreatic cancer	5.68e-05	0.00112	CcSEcCtD
Vemurafenib—Chills—Epirubicin—pancreatic cancer	5.66e-05	0.00111	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—pancreatic cancer	5.58e-05	0.0011	CcSEcCtD
Vemurafenib—Nausea—Gemcitabine—pancreatic cancer	5.56e-05	0.00109	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—pancreatic cancer	5.52e-05	0.00109	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—pancreatic cancer	5.49e-05	0.00108	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—pancreatic cancer	5.49e-05	0.00108	CcSEcCtD
Vemurafenib—Nausea—Fluorouracil—pancreatic cancer	5.47e-05	0.00108	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—pancreatic cancer	5.46e-05	0.00107	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—pancreatic cancer	5.42e-05	0.00107	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—pancreatic cancer	5.38e-05	0.00106	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—pancreatic cancer	5.31e-05	0.00104	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—pancreatic cancer	5.3e-05	0.00104	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.26e-05	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—pancreatic cancer	5.25e-05	0.00103	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—pancreatic cancer	5.24e-05	0.00103	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—pancreatic cancer	5.16e-05	0.00101	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—pancreatic cancer	5.08e-05	0.000999	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—pancreatic cancer	5.08e-05	0.000999	CcSEcCtD
Vemurafenib—CYP3A4—digestive system—pancreatic cancer	5.08e-05	0.02	CbGeAlD
Vemurafenib—CYP2D6—digestive system—pancreatic cancer	5e-05	0.0197	CbGeAlD
Vemurafenib—Dysgeusia—Doxorubicin—pancreatic cancer	4.98e-05	0.000978	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—pancreatic cancer	4.92e-05	0.000966	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—pancreatic cancer	4.9e-05	0.000962	CcSEcCtD
Vemurafenib—Cough—Epirubicin—pancreatic cancer	4.79e-05	0.000942	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—pancreatic cancer	4.77e-05	0.000937	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—pancreatic cancer	4.7e-05	0.000924	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—pancreatic cancer	4.68e-05	0.000919	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—pancreatic cancer	4.68e-05	0.000919	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.64e-05	0.000913	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—pancreatic cancer	4.55e-05	0.000894	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—pancreatic cancer	4.48e-05	0.000881	CcSEcCtD
Vemurafenib—Infection—Epirubicin—pancreatic cancer	4.45e-05	0.000875	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—pancreatic cancer	4.44e-05	0.000872	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—pancreatic cancer	4.4e-05	0.000864	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—pancreatic cancer	4.4e-05	0.000864	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—pancreatic cancer	4.35e-05	0.000856	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—pancreatic cancer	4.33e-05	0.00085	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—pancreatic cancer	4.33e-05	0.00085	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.3e-05	0.000845	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—pancreatic cancer	4.23e-05	0.000831	CcSEcCtD
Vemurafenib—Rash—Docetaxel—pancreatic cancer	4.19e-05	0.000824	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—pancreatic cancer	4.19e-05	0.000823	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—pancreatic cancer	4.19e-05	0.000823	CcSEcCtD
Vemurafenib—Headache—Docetaxel—pancreatic cancer	4.16e-05	0.000818	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.15e-05	0.000815	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—pancreatic cancer	4.12e-05	0.00081	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.08e-05	0.000803	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—pancreatic cancer	4.07e-05	0.0008	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—pancreatic cancer	4.03e-05	0.000792	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—pancreatic cancer	3.95e-05	0.000776	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—pancreatic cancer	3.9e-05	0.000766	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—pancreatic cancer	3.88e-05	0.000762	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.87e-05	0.000761	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—pancreatic cancer	3.87e-05	0.00076	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—pancreatic cancer	3.83e-05	0.000754	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.78e-05	0.000743	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—pancreatic cancer	3.61e-05	0.000709	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.58e-05	0.000704	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—pancreatic cancer	3.58e-05	0.000703	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—pancreatic cancer	3.55e-05	0.000697	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—pancreatic cancer	3.54e-05	0.000697	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—pancreatic cancer	3.3e-05	0.000649	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—pancreatic cancer	3.28e-05	0.000645	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—pancreatic cancer	3.22e-05	0.000632	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—pancreatic cancer	3.17e-05	0.000623	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—pancreatic cancer	3.07e-05	0.000603	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—pancreatic cancer	3.06e-05	0.000601	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—pancreatic cancer	2.98e-05	0.000585	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—pancreatic cancer	2.96e-05	0.000583	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—pancreatic cancer	2.93e-05	0.000577	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—pancreatic cancer	2.85e-05	0.00056	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—pancreatic cancer	2.84e-05	0.000558	CcSEcCtD
Vemurafenib—Rash—Epirubicin—pancreatic cancer	2.83e-05	0.000556	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—pancreatic cancer	2.82e-05	0.000555	CcSEcCtD
Vemurafenib—Headache—Epirubicin—pancreatic cancer	2.81e-05	0.000552	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—pancreatic cancer	2.74e-05	0.000539	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—pancreatic cancer	2.66e-05	0.000523	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—pancreatic cancer	2.64e-05	0.000518	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—pancreatic cancer	2.62e-05	0.000514	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—pancreatic cancer	2.61e-05	0.000514	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—pancreatic cancer	2.6e-05	0.000511	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—pancreatic cancer	2.46e-05	0.000484	CcSEcCtD
Vemurafenib—ALB—Metabolism—SLC2A2—pancreatic cancer	5.19e-06	9.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOTCH1—pancreatic cancer	5.19e-06	9.71e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOTCH1—pancreatic cancer	5.14e-06	9.62e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CG—pancreatic cancer	5.13e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.13e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	5.11e-06	9.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—pancreatic cancer	5.08e-06	9.5e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGF—pancreatic cancer	5.07e-06	9.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDH1—pancreatic cancer	5.06e-06	9.46e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TYMS—pancreatic cancer	5.05e-06	9.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGF—pancreatic cancer	5.01e-06	9.38e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—pancreatic cancer	4.98e-06	9.32e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGF—pancreatic cancer	4.97e-06	9.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CD—pancreatic cancer	4.96e-06	9.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.95e-06	9.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMAD4—pancreatic cancer	4.93e-06	9.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	4.91e-06	9.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CA—pancreatic cancer	4.89e-06	9.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—pancreatic cancer	4.87e-06	9.12e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTEN—pancreatic cancer	4.85e-06	9.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CD—pancreatic cancer	4.83e-06	9.04e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMP—pancreatic cancer	4.82e-06	9.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES1—pancreatic cancer	4.81e-06	9.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—pancreatic cancer	4.8e-06	8.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—pancreatic cancer	4.73e-06	8.86e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—pancreatic cancer	4.67e-06	8.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—pancreatic cancer	4.62e-06	8.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CB—pancreatic cancer	4.61e-06	8.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—pancreatic cancer	4.6e-06	8.62e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GLP1R—pancreatic cancer	4.59e-06	8.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—pancreatic cancer	4.53e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DPYD—pancreatic cancer	4.51e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CD—pancreatic cancer	4.51e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.51e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SRC—pancreatic cancer	4.5e-06	8.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CD—pancreatic cancer	4.46e-06	8.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—pancreatic cancer	4.43e-06	8.29e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CD—pancreatic cancer	4.42e-06	8.27e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.42e-06	8.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PIK3CA—pancreatic cancer	4.41e-06	8.25e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—pancreatic cancer	4.34e-06	8.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—pancreatic cancer	4.33e-06	8.11e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CB—pancreatic cancer	4.32e-06	8.09e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	4.28e-06	8.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ARG2—pancreatic cancer	4.26e-06	7.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PIK3CA—pancreatic cancer	4.23e-06	7.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TERT—pancreatic cancer	4.22e-06	7.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CG—pancreatic cancer	4.21e-06	7.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CB—pancreatic cancer	4.21e-06	7.88e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	4.17e-06	7.81e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—pancreatic cancer	4.11e-06	7.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—pancreatic cancer	4.08e-06	7.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—pancreatic cancer	4.08e-06	7.63e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—pancreatic cancer	4.06e-06	7.61e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—pancreatic cancer	4.03e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HIF1A—pancreatic cancer	4.03e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—pancreatic cancer	4.02e-06	7.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TSC2—pancreatic cancer	4.02e-06	7.53e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CD44—pancreatic cancer	4.02e-06	7.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—pancreatic cancer	4e-06	7.48e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.98e-06	7.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—pancreatic cancer	3.95e-06	7.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—pancreatic cancer	3.94e-06	7.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CB—pancreatic cancer	3.93e-06	7.36e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.93e-06	7.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—pancreatic cancer	3.91e-06	7.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.9e-06	7.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CB—pancreatic cancer	3.89e-06	7.27e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GLP1R—pancreatic cancer	3.89e-06	7.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—pancreatic cancer	3.86e-06	7.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CB—pancreatic cancer	3.85e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GCG—pancreatic cancer	3.85e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—pancreatic cancer	3.85e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DPYD—pancreatic cancer	3.82e-06	7.16e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—pancreatic cancer	3.82e-06	7.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—pancreatic cancer	3.78e-06	7.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—pancreatic cancer	3.73e-06	6.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—pancreatic cancer	3.73e-06	6.98e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMP—pancreatic cancer	3.72e-06	6.97e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	3.7e-06	6.94e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CD—pancreatic cancer	3.7e-06	6.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKBIA—pancreatic cancer	3.67e-06	6.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—pancreatic cancer	3.64e-06	6.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—pancreatic cancer	3.63e-06	6.8e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	3.63e-06	6.79e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—STK11—pancreatic cancer	3.62e-06	6.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—pancreatic cancer	3.62e-06	6.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—pancreatic cancer	3.6e-06	6.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.59e-06	6.72e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—pancreatic cancer	3.58e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—pancreatic cancer	3.55e-06	6.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—pancreatic cancer	3.55e-06	6.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—pancreatic cancer	3.52e-06	6.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGF—pancreatic cancer	3.51e-06	6.57e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—pancreatic cancer	3.49e-06	6.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.47e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—pancreatic cancer	3.46e-06	6.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—pancreatic cancer	3.46e-06	6.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—pancreatic cancer	3.45e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—pancreatic cancer	3.42e-06	6.41e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—pancreatic cancer	3.42e-06	6.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—pancreatic cancer	3.42e-06	6.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—pancreatic cancer	3.4e-06	6.36e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.4e-06	6.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—pancreatic cancer	3.37e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—pancreatic cancer	3.37e-06	6.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—pancreatic cancer	3.36e-06	6.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—pancreatic cancer	3.33e-06	6.23e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—pancreatic cancer	3.33e-06	6.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD44—pancreatic cancer	3.32e-06	6.21e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	3.26e-06	6.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—pancreatic cancer	3.25e-06	6.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—pancreatic cancer	3.25e-06	6.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—pancreatic cancer	3.24e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—pancreatic cancer	3.23e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—pancreatic cancer	3.2e-06	5.98e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GCG—pancreatic cancer	3.18e-06	5.95e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—pancreatic cancer	3.17e-06	5.93e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.16e-06	5.91e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—pancreatic cancer	3.15e-06	5.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—pancreatic cancer	3.12e-06	5.84e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—pancreatic cancer	3.11e-06	5.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—pancreatic cancer	3.11e-06	5.83e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—pancreatic cancer	3.09e-06	5.79e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—pancreatic cancer	3.09e-06	5.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—pancreatic cancer	3.07e-06	5.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—pancreatic cancer	3.06e-06	5.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—pancreatic cancer	3.04e-06	5.69e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—pancreatic cancer	3.03e-06	5.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—pancreatic cancer	3e-06	5.62e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	3e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—pancreatic cancer	3e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STK11—pancreatic cancer	2.99e-06	5.6e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—pancreatic cancer	2.98e-06	5.57e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—pancreatic cancer	2.97e-06	5.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—pancreatic cancer	2.96e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.95e-06	5.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—pancreatic cancer	2.87e-06	5.37e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	2.84e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—pancreatic cancer	2.82e-06	5.29e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—pancreatic cancer	2.82e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—pancreatic cancer	2.81e-06	5.27e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD44—pancreatic cancer	2.81e-06	5.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.81e-06	5.26e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.8e-06	5.24e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—pancreatic cancer	2.8e-06	5.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—pancreatic cancer	2.79e-06	5.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—pancreatic cancer	2.79e-06	5.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—pancreatic cancer	2.79e-06	5.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—pancreatic cancer	2.78e-06	5.21e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—pancreatic cancer	2.77e-06	5.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—pancreatic cancer	2.76e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—pancreatic cancer	2.76e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.75e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—pancreatic cancer	2.73e-06	5.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.73e-06	5.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—pancreatic cancer	2.72e-06	5.09e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—pancreatic cancer	2.71e-06	5.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCG—pancreatic cancer	2.69e-06	5.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—pancreatic cancer	2.63e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—pancreatic cancer	2.62e-06	4.9e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—pancreatic cancer	2.61e-06	4.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—pancreatic cancer	2.6e-06	4.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—pancreatic cancer	2.58e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—pancreatic cancer	2.57e-06	4.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—pancreatic cancer	2.57e-06	4.8e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—pancreatic cancer	2.56e-06	4.78e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—pancreatic cancer	2.55e-06	4.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—pancreatic cancer	2.53e-06	4.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STK11—pancreatic cancer	2.53e-06	4.74e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—pancreatic cancer	2.5e-06	4.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—pancreatic cancer	2.45e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—pancreatic cancer	2.44e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—pancreatic cancer	2.44e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—pancreatic cancer	2.41e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—pancreatic cancer	2.4e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.4e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.38e-06	4.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—pancreatic cancer	2.37e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—pancreatic cancer	2.37e-06	4.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—pancreatic cancer	2.37e-06	4.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—pancreatic cancer	2.35e-06	4.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—pancreatic cancer	2.35e-06	4.4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—pancreatic cancer	2.32e-06	4.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—pancreatic cancer	2.29e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—pancreatic cancer	2.29e-06	4.28e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—pancreatic cancer	2.22e-06	4.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—pancreatic cancer	2.21e-06	4.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—pancreatic cancer	2.19e-06	4.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—pancreatic cancer	2.18e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—pancreatic cancer	2.18e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—pancreatic cancer	2.17e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD44—pancreatic cancer	2.17e-06	4.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—pancreatic cancer	2.15e-06	4.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—pancreatic cancer	2.12e-06	3.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—pancreatic cancer	2.1e-06	3.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—pancreatic cancer	2.1e-06	3.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—pancreatic cancer	2.1e-06	3.92e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—pancreatic cancer	2.09e-06	3.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCG—pancreatic cancer	2.08e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—pancreatic cancer	2.01e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—pancreatic cancer	1.97e-06	3.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—pancreatic cancer	1.96e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STK11—pancreatic cancer	1.95e-06	3.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—pancreatic cancer	1.95e-06	3.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—pancreatic cancer	1.95e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—pancreatic cancer	1.94e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—pancreatic cancer	1.92e-06	3.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—pancreatic cancer	1.91e-06	3.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.89e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.82e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—pancreatic cancer	1.81e-06	3.38e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—pancreatic cancer	1.77e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—pancreatic cancer	1.75e-06	3.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—pancreatic cancer	1.74e-06	3.25e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	1.73e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.68e-06	3.15e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.68e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.66e-06	3.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—pancreatic cancer	1.66e-06	3.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—pancreatic cancer	1.61e-06	3.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—pancreatic cancer	1.6e-06	3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.6e-06	2.99e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.54e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—pancreatic cancer	1.53e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—pancreatic cancer	1.51e-06	2.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.45e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.43e-06	2.68e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—pancreatic cancer	1.41e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.41e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.37e-06	2.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—pancreatic cancer	1.36e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.25e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.23e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.23e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.21e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.19e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.08e-06	2.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—pancreatic cancer	1.07e-06	2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.06e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	9.46e-07	1.77e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	9.37e-07	1.75e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	8.82e-07	1.65e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—pancreatic cancer	8.72e-07	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—pancreatic cancer	8.17e-07	1.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	7.47e-07	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—pancreatic cancer	7.2e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—pancreatic cancer	6.1e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	5.76e-07	1.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—pancreatic cancer	4.71e-07	8.82e-06	CbGpPWpGaD
